Premium
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle‐cell lymphoma
Author(s) -
CorRadini Paolo,
Ladetto Marco,
Astolfi Monica,
Voena Claudia,
Tarella Corrado,
Bacigalupo Andrea,
Pileri AlessandRo
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1816.x
Subject(s) - mantle cell lymphoma , lymphoma , minimal residual disease , transplantation , medicine , polymerase chain reaction , immunoglobulin heavy chain , bone marrow , gene rearrangement , pathology , antibody , cancer research , oncology , immunology , biology , gene , biochemistry
Mantle‐cell lymphoma (MCL) is a B‐cell tumour with a usually poor prognosis, characterized by the proliferation of small cleaved lymphocytes with a diffuse growth pattern. We report a polymerase chain reaction‐based analysis of minimal residual disease in a patient who achieved complete remission after allogeneic blood cell transplantation (BCT). Rearrangement of the immunoglobulin heavy‐chain genes was used to generate a lymphoma‐specific molecular marker. Lymphoma cells were not detectable in a bone marrow sample collected 12 months after BCT. Our findings suggest that allogeneic BCT may offer a curative approach to MCL.